ATAI Life Sciences AG’s $157 Million Series D Financing Round

Federica Tiefenthaler
Tagged:

Noerr advised Catalio Capital Management LP on the deal. ATAI Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, announced…

This content is for Standard 1 Year members only.
Login Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

…

This content is for Standard 1 Year members only.
Login Join Now